FNY Investment Advisers LLC boosted its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 75.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 133,591 shares of the company's stock after buying an additional 57,625 shares during the period. FNY Investment Advisers LLC owned approximately 0.23% of Ginkgo Bioworks worth $761,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of DNA. SBI Securities Co. Ltd. acquired a new position in Ginkgo Bioworks in the fourth quarter valued at approximately $29,000. KLP Kapitalforvaltning AS bought a new stake in Ginkgo Bioworks in the fourth quarter valued at approximately $46,000. Green Alpha Advisors LLC increased its stake in Ginkgo Bioworks by 31.7% in the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after purchasing an additional 4,449 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Ginkgo Bioworks in the fourth quarter valued at approximately $116,000. Finally, Palumbo Wealth Management LLC bought a new stake in Ginkgo Bioworks in the fourth quarter valued at approximately $144,000. 78.63% of the stock is currently owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
NYSE:DNA traded up $0.03 during trading hours on Thursday, hitting $8.58. The stock had a trading volume of 905,833 shares, compared to its average volume of 1,460,328. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $18.40. The company has a market cap of $501.97 million, a price-to-earnings ratio of -0.94 and a beta of 1.25. The business's 50 day moving average is $7.75 and its 200-day moving average is $9.08.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million for the quarter, compared to the consensus estimate of $38.70 million. On average, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
